Literature DB >> 18070814

Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women.

Paul M Ridker1, Daniel I Chasman, Robert Y L Zee, Alex Parker, Lynda Rose, Nancy R Cook, Julie E Buring.   

Abstract

The primary aim of the Women's Genome Health Study (WGHS) is to create a comprehensive, fully searchable genome-wide database of >360 000 single nucleotide polymorphisms among at least 25 000 initially healthy American women participating in the ongoing NIH-funded Women's Health Study (WHS). These women have already been followed over a 12-year period for major incident health events including but not limited to myocardial infarction, stroke, cancer, diabetes, osteoporosis, venous-thromboembolism, cognitive decline, and common visual disorders such as age- related macular degeneration and cataracts. Investigations within the WGHS will seek to identify relevant patterns of genetic polymorphism that predict future disease states in otherwise healthy American women, and to evaluate patterns of genetic polymorphism that relate to multiple intermediate phenotypes including blood-based determinants of disease that were measured at baseline for each study participant. By linking genome-wide data to the existing epidemiologic databank of the parent WHS, which includes comprehensive dietary, behavioral, and traditional exposure data on each participant since cohort inception in 1992, the WGHS will also allow exploration of gene-environment and gene-gene interactions as they relate to incident disease states. Thus, with continued follow-up of the WHS, the WGHS provides a unique scientific resource-a full-cohort, prospective, genome-wide association study among initially healthy American women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070814     DOI: 10.1373/clinchem.2007.099366

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  116 in total

1.  A large-scale candidate gene association study of age at menarche and age at natural menopause.

Authors:  Chunyan He; Peter Kraft; Daniel I Chasman; Julie E Buring; Constance Chen; Susan E Hankinson; Guillaume Paré; Stephen Chanock; Paul M Ridker; David J Hunter
Journal:  Hum Genet       Date:  2010-08-24       Impact factor: 4.132

2.  Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes.

Authors:  Lu Qi; Marilyn C Cornelis; Peter Kraft; Kristopher J Stanya; W H Linda Kao; James S Pankow; Josée Dupuis; Jose C Florez; Caroline S Fox; Guillaume Paré; Qi Sun; Cynthia J Girman; Cathy C Laurie; Daniel B Mirel; Teri A Manolio; Daniel I Chasman; Eric Boerwinkle; Paul M Ridker; David J Hunter; James B Meigs; Chih-Hao Lee; Frank B Hu; Rob M van Dam
Journal:  Hum Mol Genet       Date:  2010-04-23       Impact factor: 6.150

3.  Mitochondrial uncoupling protein gene cluster variation (UCP2-UCP3) and the risk of incident type 2 diabetes mellitus: the Women's Genome Health Study.

Authors:  Robert Y L Zee; Paul M Ridker; Daniel I Chasman
Journal:  Atherosclerosis       Date:  2010-10-20       Impact factor: 5.162

4.  Common genetic variations in the vitamin D pathway in relation to blood pressure.

Authors:  Lu Wang; Audrey Chu; Julie E Buring; Paul M Ridker; Daniel I Chasman; Howard D Sesso
Journal:  Am J Hypertens       Date:  2014-03-31       Impact factor: 2.689

5.  COMT and Alpha-Tocopherol Effects in Cancer Prevention: Gene-Supplement Interactions in Two Randomized Clinical Trials.

Authors:  Kathryn T Hall; Julie E Buring; Kenneth J Mukamal; M Vinayaga Moorthy; Peter M Wayne; Ted J Kaptchuk; Elisabeth M Battinelli; Paul M Ridker; Howard D Sesso; Stephanie J Weinstein; Demetrius Albanes; Nancy R Cook; Daniel I Chasman
Journal:  J Natl Cancer Inst       Date:  2019-07-01       Impact factor: 13.506

6.  Discovery and replication of novel blood pressure genetic loci in the Women's Genome Health Study.

Authors:  Jennifer E Ho; Daniel Levy; Lynda Rose; Andrew D Johnson; Paul M Ridker; Daniel I Chasman
Journal:  J Hypertens       Date:  2011-01       Impact factor: 4.844

7.  A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium.

Authors:  Weihong Tang; Martina Teichert; Daniel I Chasman; John A Heit; Pierre-Emmanuel Morange; Guo Li; Bruno H Ch Stricker; Paul M Ridker; Aaron R Folsom; Nicholas L Smith; Nathan Pankratz; Frank W Leebeek; Guillaume Paré; Mariza de Andrade; Christophe Tzourio; Bruce M Psaty; Saonli Basu; Rikje Ruiter; Lynda Rose; Sebastian M Armasu; Thomas Lumley; Susan R Heckbert; André G Uitterlinden; Mark Lathrop; Kenneth M Rice; Mary Cushman; Albert Hofman; Jean-Charles Lambert; Nicole L Glazer; James S Pankow; Jacqueline C Witteman; Philippe Amouyel; Joshua C Bis; Edwin G Bovill; Xiaoxiao Kong; Russell P Tracy; Eric Boerwinkle; Jerome I Rotter; David-Alexandre Trégouët; Daan W Loth
Journal:  Genet Epidemiol       Date:  2013-05-05       Impact factor: 2.135

Review 8.  Gene × environment interactions in type 2 diabetes.

Authors:  Paul W Franks
Journal:  Curr Diab Rep       Date:  2011-12       Impact factor: 4.810

9.  Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL).

Authors:  Gerald S Bloomfield; Tecla M Temu; Constantine O Akwanalo; Peng-Sheng Chen; Wilfred Emonyi; Susan R Heckbert; Myra M Koech; Imran Manji; Changyu Shen; Matteo Vatta; Eric J Velazquez; Jennifer Wessel; Sylvester Kimaiyo; Thomas S Inui
Journal:  Am Heart J       Date:  2015-06-14       Impact factor: 4.749

10.  GOSR2 Lys67Arg is associated with hypertension in whites.

Authors:  Tamra E Meyer; Dov Shiffman; Alanna C Morrison; Charles M Rowland; Judy Z Louie; Lance A Bare; David A Ross; Andre R Arellano; Daniel I Chasman; Paul M Ridker; James S Pankow; Josef Coresh; Mary J Malloy; John P Kane; Stephen G Ellis; James J Devlin; Eric Boerwinkle
Journal:  Am J Hypertens       Date:  2008-12-04       Impact factor: 2.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.